Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Grid Therapeutics logo — company profile

Grid Therapeutics

Founded 2014 United States Durham, United States 4 employees Series B Total: $5.00M Biotechnology, Life Sciences +1

General Information

Company Name Grid Therapeutics
Founded Year 2014
Location United States Durham, United States +1
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Life Sciences, Medical Devices
Funding Stage Series B
Social

Get notified when Grid Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Grid Therapeutics

Grid Therapeutics is a biotech company based in Durham, North Carolina, founded in 2014. The company is built on innovative science developed by Edward F. Patz, Jr. MD and a team of scientists at Duke University Medical Center. Grid Therapeutics is focused on developing the first human-derived targeted immunotherapy for cancer. Their lead asset, "GT103," is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients. The antibody, isolated from patient's B-cells using state-of-the-art molecular genomic techniques, was discovered in exceptional outcome early-stage lung cancer patients who did not develop metastasis. Grid's approach holds promise in the field of targeted immunotherapy, offering potential breakthroughs in cancer treatment.

Taxonomy: Biotech, Immunotherapy, Cancer, Targeted therapy, Drug development, Clinical trials, Lung cancer, B-cell, Molecular genomic techniques, Phase 1, Medical research, Innovative science, Duke University Medical Center, Patient-centered therapy

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 3 •••• •••• 27 Mar 2018
Series A •••••• 1 •••• •••• 14 Sep 2017

Grid Therapeutics Alternatives & Competitors

Grid Therapeutics vs
ONA Therapeutics
ONA Therapeutics Spain

First-in-class ADCs tailored to attack advanced cancer

Series A
35 employees
Biotechnology, Health Care
Grid Therapeutics vs
Carrick Therapeutics
Carrick Therapeutics Ireland

Transformative Cancer Medicines

Series C
16 employees
Biotechnology, Health Care
Grid Therapeutics vs
Cytogen Corporation
Cytogen Corporation

Pioneering biopharmaceutical innovations for cancer patients through advanced pharmaceutical develop...

Biotechnology

FAQ About Grid Therapeutics

Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody...
Grid Therapeutics was founded in 2014.
Grid Therapeutics is headquartered in Durham, United States.
Grid Therapeutics operates in the following industries: Biotechnology, Life Sciences, Medical Devices.
Grid Therapeutics has approximately 4 employees.
Grid Therapeutics has completed 2 funding rounds, raising a total of $5.00M. The latest funding stage is Series B.
Top alternatives and competitors to Grid Therapeutics include ONA Therapeutics, Carrick Therapeutics, Cytogen Corporation, Caedo Oncology AS, Adcendo. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Grid Therapeutics and ONA Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Grid Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy